Search hospitals > Georgia > Atlanta
Emory University School of Medicine
Claim this profileAtlanta, Georgia 30322
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for AIDS
Conducts research for Sickle Cell Disease
Conducts research for Fabry Disease
295 reported clinical trials
25 medical researchers
Summary
Emory University School of Medicine is a medical facility located in Atlanta, Georgia. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Sickle Cell Disease, Fabry Disease and other specialties. Emory University School of Medicine is involved with conducting 295 clinical trials across 486 conditions. There are 25 research doctors associated with this hospital, such as Olatunji Alese, Jane L Meisel, Melinda L. Yushak, and Sagar Lonial, MD.Top PIs
Olatunji AleseEmory University Hospital/Winship Cancer Institute7 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
17 reported clinical trials
42 drugs studied
Jane L MeiselWinship Cancer Institute / Emory University School of Medicine2 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
11 reported clinical trials
24 drugs studied
Melinda L. YushakEmory University Hospital/Winship Cancer Institute7 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
11 reported clinical trials
24 drugs studied
Sagar Lonial, MDThe Winship Cancer Institute of Emory University4 years of reported clinical research
Studies Multiple Myeloma
Studies Relapse
10 reported clinical trials
20 drugs studied
Clinical Trials running at Emory University School of Medicine
Sickle Cell Disease
Prader-Willi Syndrome
Bladder Cancer
Cardiovascular Disease
Overeating
Kidney Disorders
Spinal Cord Injury
Heart Disease
Fabry Disease
Kidney Disease
Etavopivat
for Sickle Cell Anemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Recruiting2 awards Phase 3
Curative Therapies
for Sickle Cell Disease
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.
Recruiting1 award N/A4 criteria
FTX-6058
for Sickle Cell Disease
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Recruiting1 award Phase 1
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Emory University School of Medicine?
Emory University School of Medicine is a medical facility located in Atlanta, Georgia. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Sickle Cell Disease, Fabry Disease and other specialties. Emory University School of Medicine is involved with conducting 295 clinical trials across 486 conditions. There are 25 research doctors associated with this hospital, such as Olatunji Alese, Jane L Meisel, Melinda L. Yushak, and Sagar Lonial, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.